13F Data
13F filer · CIK 1617201

Prosight Management, LP

DALLAS, TX · filing since Q4 2017 · last filing Aug 14, 2026
Reported value
$580.4M
$-29.5M vs prior
Positions
36
New / sold out
5 / 15
Added / reduced
16 / 15
Turnover
27.8%
buys $165.4M · sells $194.9M
Top-10 weight
70.7%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewINSMED INC+375,609–+$40.0M
AddedBOSTON SCIENTIFIC CORP+474,726+59.7%+$20.3M
AddedIRHYTHM HOLDINGS INC+155,500+1555.0%+$18.5M
AddedLAKEFRONT BIOTHERAPEUTICS NV+493,344+31.8%+$14.8M
NewMINERALYS THERAPEUTICS INC+449,795–+$12.1M
AddedSYNDAX PHARMACEUTICALS INC+430,000+55.8%+$9.4M
AddedALNYLAM PHARMACEUTICALS INC+22,080+29.1%+$6.6M
AddedSHATTUCK LABS INC+953,438+19.1%+$6.6M
NewOPTION CARE HEALTH INC+270,716–+$5.7M
AddedNEKTAR THERAPEUTICS+75,000+10.2%+$5.2M
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedPROCEPT BIOROBOTICS CORP-1,676,731-86.2%$-37.9M
ReducedMEIRAGTX HLDGS PLC-2,539,971-96.6%$-34.3M
ReducedGENEDX HOLDINGS CORP-437,963-83.7%$-30.1M
ReducedKURA ONCOLOGY INC-1,334,736-39.8%$-14.6M
Sold outCONCENTRA GROUP HOLDINGS PAR-505,822-100.0%$-10.8M
Sold outTERNS PHARMACEUTICALS INC-202,300-100.0%$-10.7M
Sold outPHREESIA INC-1,100,000-100.0%$-9.2M
ReducedALKERMES PLC-119,243-23.2%$-6.2M
Sold outSCHRODINGER INC-510,578-100.0%$-5.8M
ReducedONKURE THERAPEUTICS INC-1,175,389-54.6%$-5.4M
20 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2017: $136.0MQ1 2018: $159.4MQ2 2018: $136.4MQ3 2018: $179.3MQ4 2018: $193.7MQ1 2019: $228.6MQ2 2019: $198.3MQ3 2019: $180.3MQ4 2019: $227.7MQ1 2020: $213.9MQ2 2020: $233.0MQ3 2020: $210.2MQ4 2020: $216.4MQ1 2021: $122.1MQ2 2021: $159.9MQ3 2021: $181.8MQ4 2021: $167.0MQ1 2022: $154.9MQ2 2022: $126.9MQ3 2022: $186.7MQ4 2022: $183.4MQ1 2023: $210.9MQ2 2023: $341.6MQ3 2023: $315.5MQ4 2023: $249.1MQ1 2024: $359.5MQ2 2024: $334.6MQ3 2024: $406.4MQ4 2024: $361.8MQ1 2025: $304.3MQ2 2025: $410.1MQ3 2025: $428.8MQ4 2025: $483.9MQ1 2026: $609.8MQ2 2026: $580.4M
Q4 2017Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1LAKEFRONT BIOTHERAPEUTICS NVSPON ADR2,043,344$61.3M10.56%
2JANUX THERAPEUTICS INCCOM3,804,481$58.4M10.07%
3NEKTAR THERAPEUTICSCOM NEW810,000$56.5M9.74%
4BOSTON SCIENTIFIC CORPCOM1,270,273$54.2M9.34%
5SHATTUCK LABS INCCOM5,957,877$41.3M7.12%
6INSMED INCCOM PAR $.01375,609$40.0M6.90%
7ALNYLAM PHARMACEUTICALS INCCOM98,080$29.5M5.09%
8SYNDAX PHARMACEUTICALS INCCOM1,200,000$26.2M4.52%
9KURA ONCOLOGY INCCOM2,021,964$22.2M3.82%
10ALKERMES PLCSHS394,389$20.7M3.56%
26 more rows. Subscribe for $29/month to see every row, download the data and use the API.